Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie

 
• By Anju Ghangurde
  
Skydivers
LUPIN HAS LICENSED ITS EARLY STAGE ONCOLOGY ASSET TO ABBVIE

More from Business

More from Scrip